While microbiome perturbations are associated with advanced chronic liver disease (ACLD), microbial disease mechanisms are poorly understood. Using multi-omics analyses of paired saliva and faecal sam...

Punjab Newsline, Chandigarh- Punjab Transport Minister Laljit Singh Bhullar held a detailed meeting with the representatives of the Punjab Roadways/PUNBUS/PRTC Contract Workers Union and the Punjab Roadways (PUNBUS) State Transport Workers Union to deliberate on their demands. The meeting was attended by the Union leaders including State President Resham Singh Gill, State General Secretaryr. Shamsher Singh Dhillon, Senior Vice President Jaspal Singh Bajwa among others. The Transport Minister was accompanied by Secretary Transport Varun Roojam, Managing Director PRTC BS Shergill, Director State Transport Rajeev Kumar Gupta along with senior officials of the Finance and Personnel Departments.

PureTech Health (PRTC) will release H1 2025 results on August 28, with analyst presentation at 9:00am EDT/2:00pm BST. Webcast available for investors on company website.

Nearly 3,000 buses of the state public sector undertakings — PRTC, Punbus and Punjab Roadways — will remain off road tomorrow, as the employees’ unions of the undertakings have gone on strike.Meanwhile, commuters are set to face a lot of inconvenience as the government has failed to make any alternative arrangement for them.After a failed dialogue with the state government over floating tenders for issuing bus permits under the kilometre scheme to private players, the unions today announced that the strike would continue till their demands were met.Harkesh Kumar, senior vice-president of the PRTC, Punbus and Punjab Roadways contract workers unions, said apart from scrapping the tenders under the kilometre scheme for private players, the unions had alleged that the Transport Minister Laljit Bhullar had failed to fulfil their demands.The government has called for another round of meeting with the union leader tomorrow to end the dialogue.

Commuters across the state faced significant travel disruptions as approximately 8,000 contractual employees of the Pepsu Road Transport Corporation (PRTC) and Punbus staged a strike across 27 depots in Punjab. The protest resulted in a halt of government-run buses, leaving many passengers stranded and chasing private buses in the rain to reach their destinations. At the new interstate bus terminus, Harkesh Vicky, vice president of the PRTC Contractual Employees Union, expressed frustration over the lack of action from the government. Despite 45 meetings with Chief Minister Bhagwant Singh Mann, finance minister Harpal Singh Cheema and transport minister Laljit Singh Bhullar, he claimed that their demands, including job regularisation and pay parity, remain unaddressed.

Vedanta Biosciences, a PureTech (NASDAQ: PRTC) Founded Entity, announced that its Phase 2 COLLECTiVE202 study of VE202 for ulcerative colitis (UC) treatment failed to meet its primary endpoint of endoscopic response. While the treatment was well-tolerated with no serious adverse events, the response rates were not statistically different from placebo.The company will now focus on its lead program VE303, currently in Phase 3 trials for recurrent Clostridioides difficile infection (CDI). VE303 previously showed promising Phase 2 results with a 30.5% absolute risk reduction compared to placebo. The program has received Fast Track and Orphan Drug designations from the FDA. Additionally, Vedanta is advancing VE707 for preventing multidrug-resistant infections, with an IND submission planned for 2026.

New subsidiary Celea Therapeutics advances Phase 3-ready deupirfenidone for IPF treatment, led by ex-Teva North America CEO. See development timeline.

Find Karaikal to Tiruchendur bus timings, fare, travel time, and route details. Plan your trip with updated PRTC bus timings & booking details.

PureTech's (Nasdaq: PRTC) Founded Entity Vor Bio (Nasdaq: VOR) has secured an exclusive global license agreement with RemeGen for telitacicept, a novel dual-target fusion protein, along with a $175 million private placement. The license agreement grants Vor Bio rights outside Greater China and includes an initial payment of $125 million ($45M upfront + $80M in warrants), with potential regulatory and commercial milestones exceeding $4 billion plus tiered royalties.Telitacicept, already approved in China for multiple autoimmune conditions, is currently in global Phase 3 trials with results expected in H1 2027. Additionally, Vor Bio appointed Dr. Jean-Paul Kress as CEO and Chairman, replacing Dr. Robert Ang.The private placement involves issuing warrants for 700 million shares at $0.25 per warrant, closing expected on June 27, 2025.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) held its Annual General Meeting on June 16, 2025, where all proposed resolutions were successfully passed. Notable outcomes include the approval of the 2024 Annual Report with 99.97% support, and the re-election of multiple directors including Dr. Robert Langer (95.43% approval) and Dr. Raju Kucherlapati (90.88% approval). Two resolutions received less than 80% approval: the Directors' Remuneration Report (72.49%) and the re-election of Ms. Kiran Mazumdar-Shaw (72.65%). The Board acknowledged these results and committed to continued shareholder engagement, promising an update within six months. Other key approvals included PricewaterhouseCoopers LLP's reappointment as auditors, authorization for share allotment, and approval for market purchase of own shares.

PureTech Health (PRTC) presented promising Phase 2b ELEVATE IPF trial results for deupirfenidone (LYT-100) at the 2025 ATS Conference. The drug demonstrated significant efficacy in treating idiopathic pulmonary fibrosis (IPF). At 825 mg TID dosing, deupirfenidone showed an 80.9% treatment effect vs. placebo, approximately 50% greater than pirfenidone's 54.1% effect. The drug slowed lung function decline to -21.5 mL over 26 weeks and preliminary 52-week data showed -32.8 mL decline, comparable to healthy older adults' natural decline. Importantly, deupirfenidone maintained favorable tolerability despite 50% higher drug exposure compared to pirfenidone. PureTech plans to meet with the FDA by Q3 2025 and aims to initiate Phase 3 trials by year-end.

PRTC workers protest in Barnala over unmet demands, including salary delays and reinstatement, threatening a statewide agitation if not addressed soon.

PureTech Health (NASDAQ: PRTC) has published new research in BMC Pulmonary Medicine revealing critical insights into the experiences of people living with Idiopathic Pulmonary Fibrosis (IPF). The study, conducted with 106 IPF patients across the US, highlighted significant challenges in diagnosis, treatment, and quality of life.Key findings include varied diagnosis timelines with frequent delays, low antifibrotic treatment uptake, and challenges in managing multiple health conditions. Nearly 90% of participants reported managing additional health challenges alongside IPF. The research also revealed that while supplemental oxygen therapy provides symptom relief, patients face logistical, financial, and emotional challenges.The study, led by Dr. Camilla Graham and conducted in collaboration with experts from the University of Alabama, Vanderbilt University Medical Center, and the Pulmonary Fibrosis Foundation, emphasizes the need for enhanced disease awareness, streamlined diagnosis, and patient-centered treatment approaches.

YouTube video by Blerd Without Fear!

Get the PRTC bus timings from Puducherry to local places and villages. Plan your PRTC bus journey with the updated Puducherry Bus Stand timetable.

Get Puducherry to Mahe bus timings, route, travel time, & bus fare. details. Plan your trip with PRTC Puducherry to Mahe and Mahe to Puducherry bus timings.

Assures early resolution of legitimate demands Punjab Newsline, Chandigarh, April 9- Punjab Finance Minister Harpal Singh Cheema held a meeting with the Punjab Roadways Punbus/PRTC Contract Workers Union on Wednesday to address their demands comprehensively. The meeting took place at his office in the Punjab Secretariat and was attended by Transport Minister Laljit Singh Bhullar and ACS (Transport) D.K. Tiwari. During the discussions, Cheema reaffirmed the Punjab government's commitment to the welfare of its employees under the leadership of Chief Minister Bhagwant Singh Mann. He said that the Cabinet Sub-Committee, which he chairs, has implemented a policy aimed at regularizing the services of numerous contract-based employees without subjecting them to legal hurdles.